827 related articles for article (PubMed ID: 17623664)
41. Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity.
Kuzina ES; Ung PM; Mohanty J; Tome F; Choi J; Pardon E; Steyaert J; Lax I; Schlessinger A; Schlessinger J; Lee S
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7819-7824. PubMed ID: 30944224
[TBL] [Abstract][Full Text] [Related]
42. Heparin is essential for optimal cell signaling by FGF21 and for regulation of βKlotho cellular stability.
An SJ; Mohanty J; Tome F; Suzuki Y; Lax I; Schlessinger J
Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2219128120. PubMed ID: 36745784
[TBL] [Abstract][Full Text] [Related]
43. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho.
Kharitonenkov A; Dunbar JD; Bina HA; Bright S; Moyers JS; Zhang C; Ding L; Micanovic R; Mehrbod SF; Knierman MD; Hale JE; Coskun T; Shanafelt AB
J Cell Physiol; 2008 Apr; 215(1):1-7. PubMed ID: 18064602
[TBL] [Abstract][Full Text] [Related]
44. FGF21 acts as a negative regulator of bile acid synthesis.
Chen MM; Hale C; Stanislaus S; Xu J; Véniant MM
J Endocrinol; 2018 May; 237(2):139-152. PubMed ID: 29615519
[TBL] [Abstract][Full Text] [Related]
45. Relevant use of Klotho in FGF19 subfamily signaling system in vivo.
Tomiyama K; Maeda R; Urakawa I; Yamazaki Y; Tanaka T; Ito S; Nabeshima Y; Tomita T; Odori S; Hosoda K; Nakao K; Imura A; Nabeshima Y
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1666-71. PubMed ID: 20080590
[TBL] [Abstract][Full Text] [Related]
46. FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes.
Chen MZ; Chang JC; Zavala-Solorio J; Kates L; Thai M; Ogasawara A; Bai X; Flanagan S; Nunez V; Phamluong K; Ziai J; Newman R; Warming S; Kolumam G; Sonoda J
Mol Metab; 2017 Nov; 6(11):1454-1467. PubMed ID: 29107292
[TBL] [Abstract][Full Text] [Related]
47. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis.
Wu X; Li Y
Aging (Albany NY); 2009 Dec; 1(12):1023-7. PubMed ID: 20157585
[TBL] [Abstract][Full Text] [Related]
48. Investigation of the Proliferative Potential of FGF21 or FGF19 in Liver-Specific FGFR4-Deficient Mice.
Wäse K; Bartels T; Schwahn U; Kabiri M
Toxicol Pathol; 2023 Jan; 51(1-2):27-38. PubMed ID: 37098695
[TBL] [Abstract][Full Text] [Related]
49. MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity.
Fu T; Kemper JK
Vitam Horm; 2016; 101():175-96. PubMed ID: 27125742
[TBL] [Abstract][Full Text] [Related]
50. FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.
Ye M; Lu W; Wang X; Wang C; Abbruzzese JL; Liang G; Li X; Luo Y
Endocrinology; 2016 Dec; 157(12):4754-4769. PubMed ID: 27690692
[TBL] [Abstract][Full Text] [Related]
51. TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway.
Díaz-Delfín J; Hondares E; Iglesias R; Giralt M; Caelles C; Villarroya F
Endocrinology; 2012 Sep; 153(9):4238-45. PubMed ID: 22778214
[TBL] [Abstract][Full Text] [Related]
52. Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.
Nakamura M; Uehara Y; Asada M; Honda E; Nagai N; Kimata K; Suzuki M; Imamura T
J Biol Chem; 2011 Jul; 286(30):26418-23. PubMed ID: 21653700
[TBL] [Abstract][Full Text] [Related]
53. Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.
Foltz IN; Hu S; King C; Wu X; Yang C; Wang W; Weiszmann J; Stevens J; Chen JS; Nuanmanee N; Gupte J; Komorowski R; Sekirov L; Hager T; Arora T; Ge H; Baribault H; Wang F; Sheng J; Karow M; Wang M; Luo Y; McKeehan W; Wang Z; Véniant MM; Li Y
Sci Transl Med; 2012 Nov; 4(162):162ra153. PubMed ID: 23197570
[TBL] [Abstract][Full Text] [Related]
54. Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress.
Yang C; Wang C; Ye M; Jin C; He W; Wang F; McKeehan WL; Luo Y
Nutr Metab (Lond); 2012 Oct; 9(1):94. PubMed ID: 23106963
[TBL] [Abstract][Full Text] [Related]
55. Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications?
Kuro-O M
Nephrol Dial Transplant; 2019 Jan; 34(1):15-21. PubMed ID: 29800324
[TBL] [Abstract][Full Text] [Related]
56. The FGFR D3 domain determines receptor selectivity for fibroblast growth factor 21.
Gupte J; Yang L; Wu X; Weiszmann J; Hecht R; Lemon B; Lindberg R; Wang Z; Li Y
J Mol Biol; 2011 May; 408(3):491-502. PubMed ID: 21392510
[TBL] [Abstract][Full Text] [Related]
57. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease.
Itoh N
Cell Tissue Res; 2010 Oct; 342(1):1-11. PubMed ID: 20730630
[TBL] [Abstract][Full Text] [Related]
58. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho.
Fu T; Kim YC; Byun S; Kim DH; Seok S; Suino-Powell K; Xu HE; Kemper B; Kemper JK
Mol Endocrinol; 2016 Jan; 30(1):92-103. PubMed ID: 26505219
[TBL] [Abstract][Full Text] [Related]
59. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts.
Patel V; Adya R; Chen J; Ramanjaneya M; Bari MF; Bhudia SK; Hillhouse EW; Tan BK; Randeva HS
PLoS One; 2014; 9(2):e87102. PubMed ID: 24498293
[TBL] [Abstract][Full Text] [Related]
60. Perturbations of fibroblast growth factors 19 and 21 in type 2 diabetes.
Roesch SL; Styer AM; Wood GC; Kosak Z; Seiler J; Benotti P; Petrick AT; Gabrielsen J; Strodel WE; Gerhard GS; Still CD; Argyropoulos G
PLoS One; 2015; 10(2):e0116928. PubMed ID: 25664662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
